Evaluate Vantage Homepage
Dire market conditions combine with a loan overhang and investor desertion to force Epizyme's hand in a low-ball takeout.
Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?
Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.
Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
But a surprise adcom for omecamtiv mecarbil might put a spanner in the works.
Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.
The Japanese drug maker has four more conjugates coming behind Enhertu, and plans to keep future successes to itself.